Stevanato Group S P A Stock Price, News & Analysis

Stevanato Group S.p.A. (NYSE: STVN) announced that all resolutions proposed at its Annual General Meeting (AGM) on June 1, 2022 were approved. This includes the approval of annual financial statements for the year ending December 31, 2021 and the distribution of dividends of EUR 0.051 per share, with a record date of June 14, 2022 and a payment date of July 13, 2022. Shareholders also granted new authorization for share buybacks and amendments to the articles of association.

Stevanato Group (NYSE: STVN) announced its participation in two upcoming investor conferences. On June 7, 2022, they will present at the 42nd Annual William Blair Growth Stock Conference in Chicago at 2:40 PM CST. The following day, on June 9, 2022, they will be at the Jefferies Healthcare Conference in New York City at 1:00 PM EST. Live audio webcasts will be available on their website, with replays accessible for 90 days.

Stevanato Group (NYSE: STVN) has announced the acquisition of a 65,000-square-meter industrial complex in Cisterna di Latina, Italy. This facility aims to enhance the company’s production capabilities in response to rising demand for its drug containment solutions. The new site will employ approximately 190 people and partially utilize renewable energy sources. Operations are set to commence in 2023, boosting the production of standard and EZ-fill® solutions. CEO Franco Moro emphasizes the strategic expansion in a major pharmaceutical hub to better serve customer needs.

Stevanato Group (NYSE: STVN) reported a 10% revenue increase in Q1 2022, totaling €212.1 million. Diluted EPS stood at €0.10, with adjusted diluted EPS at €0.11. The backlog surged 49% to €992.2 million, driven by a 29% rise in high-value solutions. Gross profit margin improved to 31.8%, although production faced temporary slowdowns due to Covid-related absenteeism. The company maintains its fiscal 2022 guidance, projecting revenue between €935 million and €945 million and adjusted diluted EPS between €0.49 and €0.51.

Stevanato Group, a global provider of drug containment and delivery solutions, announced its 2022 Annual General Meeting (AGM) will take place virtually on June 1, 2022, at 4:00 p.m. (CEST). Shareholders can access the meeting agenda, explanatory materials, and voting instructions on the company's investor relations website. Hard copies of the audited financial statements can be requested via email. The press release emphasizes the company's commitment to shareholder engagement and transparency.

Stevanato Group (NYSE: STVN) has entered an exclusive agreement with Owen Mumford to manufacture the Aidaptus® auto-injector. This partnership allows Stevanato to provide engineering and manufacturing support to biopharma companies for drug delivery. Aidaptus® is a flexible, single-use device compatible with multiple syringe sizes and drug viscosities. The collaboration aims to enhance device production efficiency and streamline market access. Stevanato will showcase Aidaptus® at Pharmapack Europe on May 18-19, highlighting its integrated manufacturing capabilities.

Stevanato Group (NYSE: STVN) will release its financial results for Q1 2022 on May 10, 2022, at 6:30 a.m. ET. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can preregister for the call or access it via a live broadcast. Additionally, a replay of the call will be available through May 24, 2022. Founded in 1949, Stevanato Group offers comprehensive solutions for the pharmaceutical, biotechnology, and life sciences industries, focusing on drug containment, delivery, and diagnostics.

Stevanato Group S.p.A. (NYSE: STVN) has filed Amendment No. 1 (Form 20-F/A) to its 2021 Annual Report with the SEC to add the Interactive Data File and provide additional information. This was filed on April 5, 2022, and the original Form 20-F was submitted on March 8, 2022.

Shareholders can access the Form 20-F/A at www.stevanatogroup.com. A printed copy is available upon request.

Stevanato Group (NYSE: STVN) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, presenting virtually on March 22, 2022 at 9:00 a.m. EDT. A live audio webcast will be accessible on their website, with a replay available for 90 days post-event. The press release includes forward-looking statements regarding the company’s business strategies and recognizes the uncertainty in predicting future events. Founded in 1949, Stevanato Group specializes in drug containment and delivery solutions for the pharmaceutical and biotechnology sectors.